← ANALYST RATINGS · TIPRANKS
Enovis (ENOV): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $31.75, the highest $34.00, the lowest $28.00. The average is +62.1% from the last price of $19.59.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $52.00 → $34.00−34.6% | Buy | +73.6% | Reiterated | 12.10.26on TipRanks 07:20 | +3.2%next day +4.1% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $51.00 → $44.00−13.7% | Buy | +124.6% | Reiterated | 05.10.26on TipRanks 09:16 | +4.5%next day −3.2% · 5 days −2.8% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $36.00 | Buy | +83.8% | Reiterated | 02.10.26on TipRanks Oct 12 09:45 | −2.3%next day +4.5% · 5 days −1.6% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $18.00 → $19.50+8.3% | Hold | −0.5% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $18.00 → $19.00+5.6% | Hold | −3.0% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $18.50 → $20.00+8.1% | Hold | +2.1% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $17.50 → $19.00+8.6% | Sell | −3.0% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $18.00 → $20.00+11.1% | Hold | +2.1% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $18.00 → $19.50+8.3% | Hold | −0.5% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $33.00 | Buy | +68.5% | Reiterated | 08.09.26on TipRanks Sep 9 06:20 | +8.2%next day −4.3% · 5 days −9.1% | ↗ |
| David Turkaly★★★★★★★★★★#11791 · hits 40% · avg −4.0% | Citizens JMP | $55.00 → $47.00−14.5% | Buy | +139.9% | Reiterated | 02.09.26on TipRanks 06:10 | −2.1%next day −5.0% · 5 days −7.9% | ↗ |
| Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% | Freedom Capital Markets | $41.00 → $36.00−12.2% | Buy | +83.8% | Reiterated | 01.09.26on TipRanks Sep 27 05:10 | −15.8%next day −2.1% · 5 days −7.4% | ↗ |
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $45.00 | Buy | +129.7% | Reiterated | 01.09.26on TipRanks Sep 2 06:55 | −15.8%next day −2.1% · 5 days −7.4% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $52.00 | Buy | +165.4% | Reiterated | 01.09.26on TipRanks 16:35 | −2.1%next day −5.0% · 5 days −7.9% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $39.00 → $36.00−7.7% | Buy | +83.8% | Reiterated | 01.09.26on TipRanks 15:05 | −15.8%next day −2.1% · 5 days −7.4% | ↗ |
| Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% | BMO Capital | $30.00 → $27.00−10.0% | Buy | +37.8% | Assigned | 01.09.26on TipRanks 14:00 | −15.8%next day −2.1% · 5 days −7.4% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 14.08.26on TipRanks 10:35 | +1.8%next day −4.6% · 5 days +1.4% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $28.00 | Hold | +42.9% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | −8.9%next day +1.8% · 5 days +2.1% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $32.00 | Buy | +63.3% | Reiterated | 07.08.26on TipRanks 08:45 | +0.5%next day −8.9% · 5 days −2.5% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $50.00 → $51.00+2.0% | Buy | +160.3% | Initiated | 28.07.26on TipRanks 06:50 | +4.3%next day +4.0% · 5 days +0.4% | ↗ |
| Rong Li★★★★★★★★★★#8516 · hits 50% · avg +3.7% | Jefferies | $40.00 | Buy | +104.2% | Reiterated | 14.07.26on TipRanks Jul 21 21:03 | −6.5%next day +3.4% · 5 days +10.4% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $45.00 → $37.00−17.8% | Buy | +88.9% | Reiterated | 08.05.26on TipRanks 08:55 | −3.5%next day −6.8% · 5 days −8.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Enovis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.82 at a price of $18.27 (+112.5%); now: $36.20 at $19.59 (+84.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 3 | 1 | 4 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.77 (from $0.71 to $0.83). Last quarter: $0.90.
Sales
Next quarter’s sales estimate — $557M (from $552M to $563M). Last quarter: $583M.
Best top-analyst consensus in the sector · Healthcare
About Enovis
- CEO: Damien McDonald
- Employees: 7,802
- 2711 Centerville Road, Wilmington, DE, 19808, US
- www.enovis.com
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Data from the stock’s TipRanks forecast page, read 33 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗